戊型肝炎酶联免疫诊断方法的建立及其应用  

Establishment and application of enzyme immunoassay to detect hepatitis E virus

作　　者：江永珍[1] 毕胜利[1] 赵洪兰[1] 李景源[1] 鲁键[1] 王培之 佟俊生 刘崇柏[1] 

机构地区：[1]中国预防医学科学院病毒学研究所,北京100052 [2]北京市第一传染病医院检验科 [3]秦皇岛市卫生防疫站

出　　处：《中华实验和临床病毒学杂志》1996年第2期169-173,共5页Chinese Journal of Experimental and Clinical Virology

摘　　要：用基因工程重组的戊型肝炎病毒(HEV)抗原 ORF3、ORF2和 ORF3-2嵌合抗原及化学合成的 ORF3多肽抗原,分别建立了酶联免疫方法(EIA),检测55份临床可凝的戊型肝炎病人血清中 HEV抗体,以 ORF3-2嵌合抗原检测的抗体阳性率最高,为94.5%(52/55),ORF3重组抗原和多肽抗原检测的抗体阳性率分别为93%(51/55)和91%(50/55),ORF2抗原检测的抗体阳性率为49%(27/55)。上述抗原的检测结果与 Genlabs HEV EIA 检测的结果比较,其符合率相应为100%,98%,96%和52%。32份经 Genlabs EIA 试剂筛选的流行病调查抗体阳性的血清,用四种抗原分别检测 ORF3-2嵌合抗原的抗体阳性数为30例,与 Genlabs 试剂的检测符合率为93.75%;ORF2抗原检出23例,符合率为71.87%;ORF3重组抗原与多肽抗原各检出17例和14例,符合率分别为53.12%和43.75%。正常人群HEV 的抗体阳性率为4%。应用嵌合抗原检测不同症状的肝病患者 HEV 抗体,肝硬化和肝癌者约17%、急性肝炎者15%、慢性肝炎者7%为抗体阳性。Solid-phase enzyme immunoassays(EIA)were developed for detecting anti-HEV immunoglobulin G (IgG)by using recombinant antigens(ORF2.ORF3 and chimeric ORF3-2)and synthetic polypeptide antigen (ORF3)from the open reading frame(ORF)2 and 3 of a Chinese virus strain.The sera were collected from patients with acute viral hepatitis(these patients except two positive for anti-HAV IgM,were negative for anti-HAV,anti- HBV and anti-HCV).Three recombinant antigens ORF3-2,ORF3 and ORF2 were used to detect the specific anti- HEV IgG among 55 HEV suspected acute patients whose HEV-IgG positive rates were 94.5%.93% and 49% respec- tively.91% was positive with the polypeptide ORF3 antigen.2% and 4% were positive in normal human group.The chimeric antigen ORF3-2 was used to detect anti-HEV IgG among clinically different patients with acute viral hepatitis (AH),chronic hepatitis(CAH),cirrhosis and carcinoma of the liver.The positive rates were 14.8%,7% and 16. 7% separately.

关 键 词：戊型肝炎病毒 病毒抗原 ELISA 诊断 

分 类 号：R512.604[医药卫生—内科学]